Zydus Lifesciences Limited has been provisionally granted by the US FDA to its 4mg Budesonide a delayed release capsule which is a move that would make the company broaden its market in the U.S. generics sector...
Expressions of interest (EoI) have been invited by the Indian Council of Medical Research (ICMR) to firms, manufacturers and research organizations that have the capability to develop and produce monoclonal antibodies (mAbs) against Nipah virus...
Roche today reported positive Phase III results for Gazyva (obinutuzumab) in adults with systemic lupus erythematosus (SLE) receiving standard therapy. The ALLEGORY study met its main goal, showing more patients achieved a four-point improvement...
Takeda has completed its seven-year Phase 3 TIDES trial of QDENGA confirming that the vaccine provides lasting and reliable protection against dengue. The study, which also looked at the effects of a booster dose, showed that QDENGA maintains...
Johnson & Johnson MedTech, a cardiac arrhythmia treatment global leader, said that new clinical and real-world results of its VARIPULSE™ Platform in pulsed field ablation (PFA) of atrial fibrillation (AF) would be revealed at the Asia Pacific...
Eli Lilly's Omvoh (mirikizumab) shows early and lasting relief in bowel urgency for patients with ulcerative colitis, reducing severity and frequency by over 50 percent in the Phase 3b LUCENT URGE study.
.png)
Lupin Digital Health, India’s leading cardiac digital-therapeutics company, has launched VITALYFE, an AI-powered cardiometabolic wellness platform designed to help India’s professionals improve their heart health...
Roche today announced that it has been awarded CE mark for its Elecsys Dengue Ag test, a high-throughput, completely automated immunoassay intended to support the diagnosis of acute dengue virus infection. This achievement represents a...
Merck & Co. and Eisai Co., Ltd. reported that their kidney cancer drug combo of Welireg and Lenvima met one main goal in a late stage trial for advanced renal cell carcinoma. The combo showed a significant improvement in progression free...
GSK has signed a global exclusive deal with Syndivia - a privately-held biotech dedicated to developing next-generation antibody-drug conjugates (ADCs) - for the advancement and commercialization of a preclinical ADC for patients with metastatic...
.jpg)
.jpg)
, CDSCO.jpg)